Episodes

  • Brenmiller Energy (NASDAQ: BNRG) COO and Co-Founder on Innovative Low-Cost Renewable Heat and Multi-Trillion Dollar Market Opportunity
    Jul 9 2025

    Send us a text

    On this week's episode of the WTR Small-Cap Spotlight, Nir Brenmiller, Chief Operating Officer, Co-Founder and Director at Brenmiller Energy (NASDAQ ticker BNRG), joined Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer of Water Tower Research, and Peter Gastreich, Energy and Sustainable Investing Analyst at Water Tower Research to discuss: 1) the company’s innovative heat storage technology that bridges the intermittency of renewable energy generation and provides clean energy in the form of steam to industrial and other customers; 2) the multi-trillion dollar market opportunity for decarbonization of heat and electrification of heat; 3) what makes the technology competitive and lower cost when compared to traditional boilers and natural gas; 4) the company’s “heat as a service” business model targeting leading corporations looking to decarbonize; and 5) the first flagship operations starting by the end of this year plus a $500 million pipeline.

    Show More Show Less
    24 mins
  • How the Biomarker Era Will Transform the CNS Treatment Landscape with Psilera CEO Dr. Chris Witowski
    Jun 30 2025

    Send us a text

    In this episode of the WTR Small-Cap | Biotech Spotlight Crossover, Water Tower Research’s Tim Gerdeman is joined by Dr. Chris Witowski, CEO of Psilera, and WTR Senior Analyst Robert Sassoon for an insightful discussion on the company’s pioneering work in neuroplastogen drug development and delivery technologies.

    Dr. Chris Witowski, CEO and Co-Founder of Psilera, an early-stage biotech company focused on developing next-generation neuroplastegens for neurological and neuropsychiatric disorders, shares his thoughts and insights on the evolution of biomarkers in the neurosciences, the latest developments and trends in CNS-focused biomarkers and the potentially transformative impact they will have on the CNS treatment landscape.

    Tune in to learn more about Psilera’s vision for the future of neurotherapeutics and how the company is working to transform the treatment landscape for CNS disorders.

    Show More Show Less
    15 mins
  • CATCH THE WAVE: Investing in Water Treatment and Solutions
    Jun 25 2025

    Send us a text

    In this WTR Symposium Series podcast, " CATCH THE WAVE: Investing in Water Treatment and Solutions ", management of Arq, Inc. (ARQ), California Water Service (CWT), National Energy Services Reunited (NESR), and Select Water Solutions (WTTR) join the Water Tower Research team including Shawn Severson, CEO and Co-founder, Jeff Robertson, Managing Director – Natural Resources, and Peter Gastreich, Senior Energy and Sustainable Investing Analyst to discuss growth strategies. The participating companies are delivering key water treatment technologies, water management solutions, and long-term infrastructure services for customers in energy, utilities, specialty materials and other industries.

    Show More Show Less
    1 hr and 13 mins
  • XCF Global (NASDAQ: SAFX) CEO and CFO on High-Growth Project Pipeline and Pure-Play SAF Investment Opportunity
    Jun 23 2025

    Send us a text

    On this week's episode of the WTR Small-Cap Spotlight, Mihir Dange, CEO of XCF Global and Simon Oxley, CFO of XCF Global, joined Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer of Water Tower Research, and Peter Gastreich, Energy and Sustainability Analyst at Water Tower Research to discuss: 1) XCF Global as the first publicly listed pure-play sustainable aviation fuel (SAF) producer in the US; 2) how decarbonizing the global aviation industry will lead to 100x demand growth for SAF; 3) status of the company’s existing SAF plant in operation since Feb 2025 and XCF’s large pipeline of new SAF projects; 4) the unique advantages of the feedstock and offtake agreements and partnership with Phillips66; and 5) the modular approach to expansion and focus on private capital financing rather than government loans.

    Show More Show Less
    31 mins
  • Stardust Power (NASDAQ: SDST) CEO on Bridging the Critical Supply and Processing Gap for Battery Grade Lithium in the US
    Jun 18 2025

    Send us a text

    On this week's episode of the WTR Small-Cap Spotlight, Roshan Pujari, Executive Chairman and CEO of Stardust Power joined Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer of Water Tower Research, and Peter Gastreich, Energy and Sustainability Analyst at Water Tower Research to discuss: 1) the critical need for developing domestic lithium refining capacity in the US, a market which is dominated by imports; 2) plans to build one of the largest battery-grade lithium refineries in the US and strategic advantages of locating in Oklahoma; 3) progress on offtake agreements including 80-100% of phase 1 supply in a non-binding agreement with Sumitomo Corp; 4) Stardust Power’s upstream integration strategy and the abundance of lithium reserves and brine assets linked to the oil and gas industry in the US; and 5) the company’s financing and capital strategy.

    Show More Show Less
    23 mins
  • Enlivex Therapeutics CEO Oren Hershkovitz, PhD Discusses Allocetra Cell Therapy and Recent Knee Osteoarthritis Data
    Jun 13 2025

    Send us a text

    Enlivex Therapeutics CEO Oren Hershkovitz, PhD joins us on another WTR Small-Cap x Biotech Spotlight crossover episode to talk about how the company’s cell therapy, Allocetra, reprograms macrophages to treat inflammatory diseases. We dive into the recent Phase 1 data in knee osteoarthritis and what to expect from the randomized Phase 2 readout later this year, as well as the market opportunity. Listen to learn more about Enlivex Therapeutics and its off-the-shelf cell therapy platform.

    Show More Show Less
    28 mins
  • Apimeds Pharmaceuticals CEO Erik Emerson Discusses Purified Bee Venom for Knee Osteoarthritis and Other Inflammatory Conditions
    Jun 11 2025

    Send us a text

    On this week’s WTR Small-Cap Spotlight, we speak with Apimeds CEO Erik Emerson about the newly NYSE listed company and the development of Apitox, a purified honeybee venom, for knee osteoarthritis and multiple sclerosis. We discuss the therapeutic properties of bee venom and the clinical/regulatory plans to bring Apitox to the US market. Listen to learn more about Apimeds and its novel approach to treat inflammatory pain.

    You can listen to this episode and more on the WTR Biotech Spotlight at the links below!

    Apple: https://podcasts.apple.com/us/podcast/wtr-biotech-spotlight/id1795488592

    Spotify: https://open.spotify.com/episode/7KUMWuGavyAuDEs2527rp2?si=22adef2e0f304634

    Show More Show Less
    30 mins